Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ayala Pharmaceuticals
Biotech
Immunome pays $50M for Ayala's phase 3 desmoid tumor drug
Two months after SpringWorks secured the first FDA approval for desmoid tumors, Immunome has bought a drug it claims could be more effective.
James Waldron
Feb 6, 2024 9:50am
Ayala, Advaxis merger means new leadership team—Chutes & Ladders
Oct 21, 2022 9:30am
Ayala and Advaxis fuse together to pool funds for lead programs
Oct 19, 2022 11:00am
Ayala's ex-BMS drug shows promise in triple-negative breast cancer
Jun 2, 2019 9:00am
